RT Journal Article
SR Electronic
A1 Mosley, Mary
T1 Tralokinumab Reduced Acute Exacerbations in a Phase 2 Study of Severe Asthma
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 11
SP 11
OP 11
DO 10.1177/155989771411004
UL http://mdc.sagepub.com/content/14/11/11.1.abstract
AB Tralokinumab, a human immunoglobulin-G4 monoclonal antibody, potently and specifically neutralizes interleukin (IL)-13, a pleiotropic cytokine thought to be a central mediator of asthma [Mitchell J et al. Curr Opin Investig Drugs 2010]. This article presents the overall results from A Phase 2b, Randomized, Double-Blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma [NCT01402986; Brightling CE et al. Am J Crit Care Med 2014].